🔗 Share this article

Ministers and senior MPs have expressed alarm that the United Kingdom's recent agreements with the US administration are "fundamentally unstable." This follows revelations that a so-called "milestone" deal on pharmaceutical tariffs, which promises zero tariffs in exchange for the NHS increasing its costs, lacks any formal legal text beyond broad headline terms contained within government press releases.

A Deal Without Detail

The arrangement concerning medicines, hailed as a "generational" achievement, exists as an "agreement in principle" without formal ratification. Observers point out that the official announcements from the UK and US governments describe the deal in sharply different terms. The British version celebrates securing "zero per cent tariffs" as a unique achievement, while the American announcement dwells on the commitment for the NHS to pay 25% more for new medications.

"The danger exists that the UK government has promised concessions to increase medicine costs in return for nothing more than a assurance from President Trump," stated David Henig, a trade policy analyst. "It is documented he has a record of not following through on agreements."

Wider Concerns Amidst a Suspended Agreement

Anxieties have been intensified by Washington's recent decision to put on ice the major technology agreement, which was previously called "a generational step-change" in the bilateral relationship. The US cited a insufficient movement from the UK on lowering trade barriers as the reason for the pause.

Furthermore, concessions secured for British farmers as part of an May trade agreement have still not been formally signed off by the US, despite a looming January deadline. "We have been informed that that the US has not yet signed off the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

Privately, ministers have expressed concerns that the government's deals with Washington are lacking substance. One minister described the series of agreements as "resting on shaky ground," while another described the situation as the "current reality" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, a senior MP on the health committee, argued: "Perhaps most shocking than Trump's temper tantrums is the UK government's credulous faith that his administration is a good faith actor. The NHS is of vital importance."

Government Downplays Risks, Points to Gains

Government figures have downplayed the chances of the US withdrawing from the pharmaceuticals deal. One source suggested the US pharmaceutical industry itself had been lobbying for the agreement, wanting clarity on imports and pricing, making it more concrete than the paused tech deal.

Officials admit that instability is a feature of dealing with the Trump administration. However, they maintain that the UK has secured concrete outcomes for businesses, such as reduced duties on automobiles compared to other nations. "Securing 25% steel tariffs, which is better than the rate for the rest of the world, is a solid gain," one official said.

Yet, delays have arisen in implementing the May tariff agreement. Promised access for British beef have yet to be finalized, and the commitment to "remove tariffs on British steel and aluminium" has not been fulfilled, with tariffs remaining at 25%.

Looking ahead, the two sides have scheduled to restart talks on the paused tech prosperity deal in January, following what were described as "productive" meetings between UK and US officials in Washington.